Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Stress Prevention and Stress Management Techniques IV01:26

Stress Prevention and Stress Management Techniques IV

Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
Bulimia Nervosa01:30

Bulimia Nervosa

Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the performance of Hungary's primary health care system during the COVID-19 pandemic: findings from the cross-sectional PRICOV-19 study.

BMC primary care·2026
Same author

[Hungarian primary care: facts, problems and expectations].

Orvosi hetilap·2026
Same author

Long-Term Effectiveness of a School- and Community-Based Intervention for the Prevention of Childhood Obesity in High-Risk Families Across Europe: The Feel4Diabetes Study.

Pediatric obesity·2026
Same author

Evaluation of an AI-Supported Nutrition Application (WiseFood) in a Living Lab Context: Protocol for a User Needs Assessment, Co-Design, and Feasibility Testing.

JMIR research protocols·2026
Same author

General practitioner residents' mental health and satisfaction during their vocational training.

BMC primary care·2026
Same author

The revised-FINDRISC: A tool for type 2 diabetes risk screening across diverse populations incorporating sociodemographic indicators.

Annals of epidemiology·2026

Related Experiment Video

Updated: May 12, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K

ECONOMIC BURDEN OF OBESITY IN HUNGARY.

Emese Antal, Péter Torzsa, Imre Rurik

    Annals of Nutrition & Metabolism
    |September 15, 2025
    PubMed
    Summary

    Obesity-related healthcare costs in Hungary were substantial in 2019 and 2022, impacting public spending and patient co-payments. Targeted public health policies and education are crucial for reducing these significant economic burdens.

    Area of Science:

    • Public Health
    • Health Economics
    • Epidemiology

    Background:

    • Obesity poses a significant threat to public health and incurs substantial economic costs due to related complications.
    • Obesity-related complications (ORCs) contribute to increased healthcare utilization and expenditures.

    Purpose of the Study:

    • To calculate obesity-related public expenditures in Hungary for 2019 and 2022.
    • To estimate patient contributions to healthcare costs associated with obesity before and after the COVID-19 pandemic.

    Main Methods:

    • Data on expenditures for patients with obesity were obtained from the National Health Insurance Fund database.
    • Financial information included inpatient/outpatient services and reimbursements for medications and healing aids.

    Related Experiment Videos

    Last Updated: May 12, 2026

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
    14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    9.0K

    Main Results:

    • Obesity-related morbidities accounted for 10-12% of public healthcare cases.
    • National public healthcare expenses for obesity were approximately HUF 144 billion (2019) and HUF 133 billion (2022).
    • Patient co-payments were estimated at HUF 34 billion (2019) and HUF 43 billion (2022), with Type 2 diabetes and hypertension being the costliest conditions.

    Conclusions:

    • Reducing obesity-related expenses requires effective education and public health policies for prevention and weight management.
    • Standardized international methods are needed for consistent obesity cost calculations.